Cargando…

Dysregulated Peripheral Invariant Natural Killer T Cells in Plaque Psoriasis Patients

Background: Psoriasis is a common immune-mediated skin disease that involves T-cell-mediated immunity. Invariant natural killer T (iNKT) cells are a unique lymphocyte subpopulation that share properties and express surface markers of both NK cells and T cells. Previous reports indicate that iNKT cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yifan, Chen, Youdong, Chen, Zeyu, Zhang, Xilin, Guo, ChunYuan, Yu, ZengYang, Xu, Peng, Sun, Lei, Zhou, Xue, Gong, Yu, Yu, Qian, Shi, Yuling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850372/
https://www.ncbi.nlm.nih.gov/pubmed/35186952
http://dx.doi.org/10.3389/fcell.2021.799560
_version_ 1784652583211630592
author Hu, Yifan
Chen, Youdong
Chen, Zeyu
Zhang, Xilin
Guo, ChunYuan
Yu, ZengYang
Xu, Peng
Sun, Lei
Zhou, Xue
Gong, Yu
Yu, Qian
Shi, Yuling
author_facet Hu, Yifan
Chen, Youdong
Chen, Zeyu
Zhang, Xilin
Guo, ChunYuan
Yu, ZengYang
Xu, Peng
Sun, Lei
Zhou, Xue
Gong, Yu
Yu, Qian
Shi, Yuling
author_sort Hu, Yifan
collection PubMed
description Background: Psoriasis is a common immune-mediated skin disease that involves T-cell-mediated immunity. Invariant natural killer T (iNKT) cells are a unique lymphocyte subpopulation that share properties and express surface markers of both NK cells and T cells. Previous reports indicate that iNKT cells regulate the development of various inflammatory diseases. IL-17 is a key cytokine in the pathogenesis of psoriasis and a key therapeutic target. Secukinumab is a fully human IgG1κ antibody that targets IL-17A, thereby antagonizing the biological effects of IL-17. Objective: To explore the expression of iNKT cells in psoriasis patients and the effect of secukinumab on them. Methods: We examined the frequencies of iNKT cells, Tregs, naïve and memory CD4(+)and CD8(+)T cells in the PBMCs as well as their cytokine production in a cohort of 40 patients with moderate-to-severe plaque psoriasis and 40 gender- and age-matched healthy controls. We further collected peripheral blood of another 15 moderate-to-severe plaque psoriasis patients who were treated with secukinumab and evaluated the proportion of iNKT cells in the PBMCs at baseline and week 12. Results: The frequencies of conventional CD4(+) T cells, CD8(+) T cells, and Tregs in the PBMCs were comparable between psoriasis patients and healthy controls, but the frequencies of Th17 cells, Tc1 cells and Tc17 cells were increased in psoriasis patients. The frequency of peripheral iNKT cells and CD69(+) iNKT cells was significantly decreased in psoriasis patients. Both iNKT2 cells and iNKT17 cells were increased in psoriasis patients, but the ratio of iNKT2 cells vs iNKT17 cells was significantly reduced in psoriasis patients. After receiving secukinumab, the proportion of iNKT cells in the PBMCs of patients was increased, while the proportion of iNKT17 cells was decreased. Conclusion: Dysregulated iNKT cells may be involved in the pathogenesis of psoriasis and secukinumab may play a regulatory role on iNKT cells.
format Online
Article
Text
id pubmed-8850372
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88503722022-02-18 Dysregulated Peripheral Invariant Natural Killer T Cells in Plaque Psoriasis Patients Hu, Yifan Chen, Youdong Chen, Zeyu Zhang, Xilin Guo, ChunYuan Yu, ZengYang Xu, Peng Sun, Lei Zhou, Xue Gong, Yu Yu, Qian Shi, Yuling Front Cell Dev Biol Cell and Developmental Biology Background: Psoriasis is a common immune-mediated skin disease that involves T-cell-mediated immunity. Invariant natural killer T (iNKT) cells are a unique lymphocyte subpopulation that share properties and express surface markers of both NK cells and T cells. Previous reports indicate that iNKT cells regulate the development of various inflammatory diseases. IL-17 is a key cytokine in the pathogenesis of psoriasis and a key therapeutic target. Secukinumab is a fully human IgG1κ antibody that targets IL-17A, thereby antagonizing the biological effects of IL-17. Objective: To explore the expression of iNKT cells in psoriasis patients and the effect of secukinumab on them. Methods: We examined the frequencies of iNKT cells, Tregs, naïve and memory CD4(+)and CD8(+)T cells in the PBMCs as well as their cytokine production in a cohort of 40 patients with moderate-to-severe plaque psoriasis and 40 gender- and age-matched healthy controls. We further collected peripheral blood of another 15 moderate-to-severe plaque psoriasis patients who were treated with secukinumab and evaluated the proportion of iNKT cells in the PBMCs at baseline and week 12. Results: The frequencies of conventional CD4(+) T cells, CD8(+) T cells, and Tregs in the PBMCs were comparable between psoriasis patients and healthy controls, but the frequencies of Th17 cells, Tc1 cells and Tc17 cells were increased in psoriasis patients. The frequency of peripheral iNKT cells and CD69(+) iNKT cells was significantly decreased in psoriasis patients. Both iNKT2 cells and iNKT17 cells were increased in psoriasis patients, but the ratio of iNKT2 cells vs iNKT17 cells was significantly reduced in psoriasis patients. After receiving secukinumab, the proportion of iNKT cells in the PBMCs of patients was increased, while the proportion of iNKT17 cells was decreased. Conclusion: Dysregulated iNKT cells may be involved in the pathogenesis of psoriasis and secukinumab may play a regulatory role on iNKT cells. Frontiers Media S.A. 2022-02-03 /pmc/articles/PMC8850372/ /pubmed/35186952 http://dx.doi.org/10.3389/fcell.2021.799560 Text en Copyright © 2022 Hu, Chen, Chen, Zhang, Guo, Yu, Xu, Sun, Zhou, Gong, Yu and Shi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Hu, Yifan
Chen, Youdong
Chen, Zeyu
Zhang, Xilin
Guo, ChunYuan
Yu, ZengYang
Xu, Peng
Sun, Lei
Zhou, Xue
Gong, Yu
Yu, Qian
Shi, Yuling
Dysregulated Peripheral Invariant Natural Killer T Cells in Plaque Psoriasis Patients
title Dysregulated Peripheral Invariant Natural Killer T Cells in Plaque Psoriasis Patients
title_full Dysregulated Peripheral Invariant Natural Killer T Cells in Plaque Psoriasis Patients
title_fullStr Dysregulated Peripheral Invariant Natural Killer T Cells in Plaque Psoriasis Patients
title_full_unstemmed Dysregulated Peripheral Invariant Natural Killer T Cells in Plaque Psoriasis Patients
title_short Dysregulated Peripheral Invariant Natural Killer T Cells in Plaque Psoriasis Patients
title_sort dysregulated peripheral invariant natural killer t cells in plaque psoriasis patients
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850372/
https://www.ncbi.nlm.nih.gov/pubmed/35186952
http://dx.doi.org/10.3389/fcell.2021.799560
work_keys_str_mv AT huyifan dysregulatedperipheralinvariantnaturalkillertcellsinplaquepsoriasispatients
AT chenyoudong dysregulatedperipheralinvariantnaturalkillertcellsinplaquepsoriasispatients
AT chenzeyu dysregulatedperipheralinvariantnaturalkillertcellsinplaquepsoriasispatients
AT zhangxilin dysregulatedperipheralinvariantnaturalkillertcellsinplaquepsoriasispatients
AT guochunyuan dysregulatedperipheralinvariantnaturalkillertcellsinplaquepsoriasispatients
AT yuzengyang dysregulatedperipheralinvariantnaturalkillertcellsinplaquepsoriasispatients
AT xupeng dysregulatedperipheralinvariantnaturalkillertcellsinplaquepsoriasispatients
AT sunlei dysregulatedperipheralinvariantnaturalkillertcellsinplaquepsoriasispatients
AT zhouxue dysregulatedperipheralinvariantnaturalkillertcellsinplaquepsoriasispatients
AT gongyu dysregulatedperipheralinvariantnaturalkillertcellsinplaquepsoriasispatients
AT yuqian dysregulatedperipheralinvariantnaturalkillertcellsinplaquepsoriasispatients
AT shiyuling dysregulatedperipheralinvariantnaturalkillertcellsinplaquepsoriasispatients